This trial is testing a new cancer drug, camsirubicin, to see if it is safe and effective in treating advanced soft tissue sarcomas. The primary endpoint is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of camsirubicin. Secondary endpoints include safety, progression-free survival (PFS), time to progression (TTP), overall response rate (ORR), duration of response (DoR), overall survival (OS), and pharmacokinetics (PK).
2 Primary · 1 Secondary · Reporting Duration: 3 weeks after first injection
21 Total Participants · 1 Treatment Group
Primary Treatment: Camsirubicin · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: